Gofore May sales were somewhat below our estimate, and day-adjusted organic growth remains in slight...
Magle has announced an update on the ongoing negotiations with its principal bondholders regarding a...
DO & CO closed FY 25/26 with a strong Q4. Sales grew 13% yoy to € 594m and EBIT improved 10% yoy to ...
Yesterday, Bittium received a EUR 14m order from the Finnish Defence Forces for SDR radios to be del...
Redeye reviews BioInvent’s second key opinion leader (KOL) event of 2026, highlighting clinical deve...
Redeye adjusts its forecasts following the FDA's issuance of another complete response letter (CRL) ...
Redeye has raised its forecasts on the back of an upbeat Q4 report.
Redeye updates on Xspray following a management call that provided some clarification on the Nilopki...
Redeye was quite surprised by the strong growth in Q4, almost 10% organically.
Yesterday, 2.72m already existing MHP Hotel shares were successfully placed (oversubscribed), equiva...
Redeye provides an update on AlzeCure Pharma following the out-licensing of Alzstatin ACD680 to Eli ...
We trim 2026E-28E adjusted EBITA by 2% ahead of the Q2 report due on 15 July, mainly due to persiste...
Bittium today published new solutions to improve its position.
* Merchant-first platform in a fragmented Nordic market * Loan book growth transforms volumes into r...
Redeye comments on 4C Group’s fully secured rights issue of approximately SEK54m, with a potential o...
AlzeCure has out-licensed the global rights for Alzstatin ACD680 to Eli Lilly in a deal potentially ...
We expect healthy demand to have continued into Q2/26, which, together with a more balanced cost bas...
Kan bolaget skala upp genom ett skifte i intäktsmixen, eller skapar förvärvsstrategin problem med in...
This morning, Moberg Pharma and Karo Healthcare announced an expansion of their licensing agreement ...
A more supportive jackpot environment should drive a visible acceleration in ZEAL's Q2 billings.
